- Title
- A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087)
- Creators
- Susana Banerjee - Royal Marsden NHS Foundation TrustRamez Eskander - University of California, San DiegoPatricia Roxburgh - Beatson West of Scotland Cancer Center, Glasgow, United KingdomDavid O'Malley - The Ohio State UniversityAna Oaknin - Vall d'Hebron Institute of OncologyJoyce Barlin - Women’s Cancer Care Associates, Albany, NY, United StatesEls Van Nieuwenhuysen - University Hospital Leuven, Leuven, BelgiumCharles Anderson - Oncology Associates of Oregon, Eugene, OR, United StatesJean-François Baurain - Clinique Universitaire St-Luc, Brussels, BelgiumLindsay Brubaker - University of Colorado, Aurora, CO, United StatesJoo Ern Ang - Cambridge University Hospitals NHS Foundation TrustNoelle Cloven - Fondazione Ricerca TraslazionaleAndrés Redondo - Hospital Universitario La PazBradley Monk - PhoenixIsabelle Ray-Coquard - Centre Léon BérardKathleen Moore - University of Oklahoma Health Sciences CenterDominique Berton - Institut de Cancérologie de l'OuestMegan Sardone - Fondazione Ricerca TraslazionaleDiane Marsolini - Fondazione Ricerca TraslazionaleShannon Westin - The University of Texas MD Anderson Cancer Center
- Publication Details
- Gynecologic oncology, Vol.190, pp.S302-S302
- Publisher
- Elsevier Inc
- Identifiers
- 991006118537602656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087)
Gynecologic oncology, Vol.190, pp.S302-S302
11/2024
Metrics
2 Record Views